Currently available pharmaceuticals exert beneficial effects on morbidity and mortality in heart failure. Only cardiac transplantation, however, provides a definitive solution to the irreversible loss of cardiomyocytes in the failing heart. The limited availability of donor hearts leaves the vast majority of afflicted patients in need. The need for innovative approaches to improve care for these patients is apparent.